CAPS’ new quality assurance program requires 100% release testing of all of its compounded drugs and other products. The Test, Hold, and Release (THR) program is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch.